Metastatic Breast Cancer
Conditions
Brief summary
Genomic analysis for metastatic breast cancer(MBC) patients * Participant (Inclusion criteria) 1. Patients who diagnosed metastatic/stage IV breast cancer 2. Patients who were not received treatment for metastatic breast cancer on palliative setting * Process (1) Tissue/ Blood sample * At diagnosis, MBC tissue / blood sample (20cc) will be obtained. * At disease progression after 1st line treatment for MBC, blood sample (20cc) will be obtained (tissue; optional) (2) WES, RNASeq, ctDNA, Exosome * We will analyze genomic characteritics using WES, RNASeq, ctDNA, Exosome.
Interventions
DIAGNOSTIC_TESTGenomic analysis
WES, RNASeq, ctDNA, Exosome
Sponsors
Samsung Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who diagnosed ad metastatic breast cancer * Patients who were not received treatment on palliative setting
Exclusion criteria
* Patients who did not agree this study * Patients who did not have any pathologic specimen at MBC diagnosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Genomic profiling of MBC patients | 60 months | Gemetic alteration frequency, the association between genetic alteration and survival |
Countries
South Korea
Contacts
Primary ContactYoung-Hyuck Im, MD,PhD
Backup ContactJi-Yeon Kim, MD
Outcome results
None listed